Bipartisan bill would increase access to Medicare data

Bipartisan legislation introduced by Senators Tammy Baldwin (D-Wisc.) and John Thune (R-S.D.) would increase the transparency of healthcare costs in Medicare.

"Medicare is the single largest payer of healthcare services in the country, spending over $600 billion each year. But we know very little about what we are paying for,” said Baldwin a release. “The Quality Data, Quality Healthcare Act provides access to that data and puts it into the hands of those who can best use it, helping doctors make more informed decisions and improving how we deliver healthcare.”

“Almost every business relies on metrics to evaluate what it is doing well and what it needs to improve, CMS—America’s largest health care payer should be no different,” said Thune. “Providing access to data that can be used to evaluate healthcare services is a critical component of increasing transparency and reducing healthcare costs. I hope our colleagues will join us in supporting this common-sense measure to improve the quality of healthcare while reducing costs.”

As the largest payer of healthcare in the United States, the Centers for Medicare & Medicaid Services (CMS) sits on a wealth of information that can help inform healthcare providers in making better decisions that will improve patient care and reduce costs. Economists have argued that expanding access to Medicare cost and utilization data will increase efficiency in healthcare delivery, reduce costs and improve the quality of care.

The senators said that recent efforts by the administration to increase access to Medicare data are promising, but lack the necessary detail and context to be most useful. They said that the Qualified Entity (QE) program is a more promising effort created by Congress that allows organizations to access and analyze comprehensive Medicare data for select purposes. "The QE program has the potential to empower our nation’s healthcare decision-makers to make better choices. However, current law is far too restrictive on which organizations can participate in the QE program, what QEs can do with the Medicare data once they have received it and the degree to which QEs can support their own data maintenance infrastructures," they said.

The Quality Data, Quality Healthcare Act would allow organizations receiving Medicare data to analyze and redistribute it to authorized subscribers, such as insurers, health systems and physicians, so that subscribers can make more informed decisions. It also would permit those entities to charge a fee to their subscribers so that the organizations can conduct robust analyses to improve healthcare quality and reduce costs. 

The senators first introduced this bipartisan legislation last Congress. It is supported by a broad coalition, including: AARP, American Academy of Family Physicians, ASC Association, Health Collaborative, National Coalition on Health Care, National Association of Manufacturers, National Consumers League, National Retail Federation, Network for Regional Healthcare Improvement, Pacific Business Group on Health, and Midwest Business Group on Health.

Access a summary of the act.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.